Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Ormaplatin"'
Publikováno v:
Dalton Transactions. 47:5548-5552
Ormaplatin ([Pt(dach)Cl4]) represents one of the three primary structural prototypes of Pt(iv) anticancer-active prodrugs. The reduction of ormaplatin by an extended series of thiols has been studied kinetically in a broad pH range. A novel and remar
Publikováno v:
Transition Metal Chemistry. 41:295-304
N-acetyl-l-cysteine (NAC) is an antioxidant and a supplement and has been demonstrated to have protective effects for a variety of toxic effects of heavy metals. Although previous works have shown that NAC can ameliorate the severe toxic effects of c
Publikováno v:
Dalton Transactions. 45:11326-11337
The reductions of Pt(iv) anticancer prodrugs [Pt(dach)Cl4] (ormaplatin/tetraplatin), cis-[Pt(NH3)2Cl4], and cis,cis,trans-[Pt(NH3)2Cl2Br2] by the several dominant reductants in human plasma have been characterized kinetically in this work, including
Publikováno v:
Transition Metal Chemistry. 40:347-353
Ormaplatin ([Pt(dach)Cl4]) is a prototypical of Pt(IV) anticancer prodrug; its reduction by 3,6-dioxa-1,8-octanedithiol (DODT, a model compound for the active site of thioredoxin), has been characterized at 25.0 °C and in a wide pH range by rapid sc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Transition Metal Chemistry. 39:127-133
Sodium thiosulfate has been utilized as a rescuing agent for relief of the toxic effects of cisplatin and carboplatin. In this work, we characterized the kinetics of reactions of the trans-dichloro-platinum(IV) complexes cis-[Pt(NH3)2Cl4], ormaplatin
Publikováno v:
Bioorganicmedicinal chemistry letters. 26(17)
The reduction of ormaplatin (tetraplatin), a prototype for Pt(IV) anticancer prodrugs, by glutathione (GSH) was kinetically characterized over a wide pH range at 25.0 °C and 1.0 M ionic strength. The reduction follows overall second-order kinetics,
Autor:
Walter J. Loos, Erik A.C. Wiemer, Anton W. M. Boersma, Jozien Helleman, Herman Burger, Els M.J.J. Berns, Ron H.J. Mathijssen, Adja Zoumaro-Djayoon
Publikováno v:
British Journal of Pharmacology. 159:898-908
BACKGROUND: Solute carriers (SLCs), in particular organic cation transporters (OCTs), have been implicated in the cellular uptake of platinum-containing anticancer compounds. The activity of these carriers may determine the pharmacokinetics and the s
Autor:
Michael I. Koukourakis
Publikováno v:
Seminars in Oncology. 30:18-30
A large body of experimental evidence suggests that amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD) is a selective cytoprotector of normal tissues. Nevertheless, several experimental studies, most of which were conducted in the early 1
Publikováno v:
British Journal of Cancer
Platinum-based drugs are very useful in cancer therapy but are associated with neurotoxicity in the clinic. To investigate the mechanism of neurotoxicity, dorsal root ganglia of rats treated with various platinum drugs were studied. Cell body, nuclea